Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2002-09-27
2004-06-15
Kishore, Gollumudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S001000, C514S183000, C514S506000, C514S304000, C514S327000, C514S331000, C514S529000
Reexamination Certificate
active
06750195
ABSTRACT:
This invention relates to treatment of conditions associated with bladder hypersensitivity, and conditions associated with a poorly functioning bladder.
European Journal of Pharmacology 146 (1988), 187-188, and Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non classical 5-hydroxytryptamine receptor, now designated the 5-HT
4
receptor, and that tropisetron (ICS 205-930), which is also a 5-HT
3
receptor antagonist, acts as an antagonist at this receptor and metoclopramide is an agonist at this receptor.
WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT
4
receptor antagonists in the treatment of atrial arrhythmias and stroke.
Metoclopramide has been shown to be effective in treating a poorly functioning bladder, (Scand. J. Urology and Nephrology, 13:79-82 (1979) but this has not been specifically linked to any known action of metoclopramide.
There are reports in the literature of 5-HT
4
receptors potentiating contractions in human bladder (Br. J. Pharmacol, 61, 115P) and inhibiting contractions in monkey bladder (2nd International Symposium on Serotonin, Houston, September 1992, page 86).
We have now discovered that a compound which acts as an antagonist at 5-HT
4
receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT
4
receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy. When used herein the term ‘5-HT
4
modulator’ is used to denote antagonists and agonists.
The invention therefore provides a method for the treatment and/or prophylaxis of conditions associated with bladder hypersensitivity and conditions associated with a poorly functioning bladder in mammals, including humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis, an effective and/or prophylactic amount of a 5-HT
4
modulator.
5-HT
4
modulators may be identified according to standard methods, such as those described hereinafter, and that described in Naunyn-Schmiedeberg's Arch Pharmacol. 342, 619-622.
REFERENCES:
patent: 5318977 (1994-06-01), Becker et al.
patent: 5362756 (1994-11-01), Riviere et al.
patent: 5492919 (1996-02-01), Sanger et al.
patent: 5580885 (1996-12-01), King et al.
patent: 0 467 365 (1992-01-01), None
patent: 0 501 322 (1992-09-01), None
patent: 76530 (1961-09-01), None
patent: WO 91/16045 (1991-10-01), None
patent: WO 92/14727 (1992-09-01), None
patent: WO 93/02677 (1993-02-01), None
patent: WO 93/03725 (1993-03-01), None
patent: WO 93/05038 (1993-03-01), None
patent: WO 93/05040 (1993-03-01), None
patent: WO 93/08187 (1993-04-01), None
Etienne, M.; Verlinden, M.; Brassinne, M.; “Treatment with Cisapride of the Gastrointestinal and Urological Sequelae of Spinal Cord Transection: Case Report”, Paraplegia, 26 (1998), pp 162-164.*
A.P.C.W. Ford and M.S.Kava, Chapter 8: “5-HT4 receptors in lower urinary tract tissues”, pp. 171-193, in: “5-HT4 receptors in the Brain and the Periphery”, ed. R.M. Englen, Springer-Verlag and RG Landes & Co, 1998.
M.V. Waikar, APDW Ford et al.,Br. J. Pharmacol., 1994, 111(1), 213-218.
R.M. Eglen et al.,Br. J. Pharmacol., vol. 107, Dec. 1992 Proceedings Supplement, 439P.
J. Bermudez et al.,J. Med. Chem., 1990, 33, 1924-1929.
K.H. Buchheit and R. Gamse,Naunyn-Schmiedeberg's Arch. Pharmacol., 1991, 343 (Suppl.), R101.
K.H. Buchheit, R. Gamse et al.,Eur. J. Pharmacol., 1991, 200, 373-374.
ML Cohen et al.,J. Pharmacol. Exptl. Therap., 1989, 248, 197-201.
M. Corsi et al.,Br. J. Pharmacol., 1991, 104, 709.
D.A. Craig et al.,J. Pharmacol. Exp. Therapeutics, 1990, 252(3), 1378-1386.
G.H. De Groot, et al.,Paraplegia, vol. 26, No. 3, 1988, pp. 159-161.
A. Dumuis et al.,Eur. J. Pharmacol., 1988, 146, 187-188.
A. Dumuis et al.,Naunyn-Schmiedeberg's Arch. Pharmacol., 1989, 340, 403-410.
A. Dumuis et al.,Naunyn-Schmiedeberg's Arch. Pharmacol., 1992, 345, 264-269.
C.J. Elswood et al.,Eur. J. Pharmacol., 1991, 196, 149-155.
M. Etienne, et al.,Paraplegia, vol. 26, No. 3, 1988, pp. 162-164.
A.P.C.W. Ford et al., “5HT4 receptor agonism inhibits neuronally-mediated responses in monkey urinary bladder”, 2nd International Symposium on Serotonin, Houston, Sep. 1992, p. 53.
R. Gamse,Cancer Treatment Reviews, 1990, 17, 301-305.
P. Hanson, et al.,Acta Belg. Med. Phys., vol. 12, No. 3, 1989, pp. 81-88.
J.R. Hindmarsh et al.,Br. J. Pharmacol., 1977, 61, 115P.
A.J. Kaumann,Naunyn-Schmiedeberg's Arch. Pharmacol., 1990, 342, 619-622.
A.J. Kaumann et al.,Br. J. Pharmacol., 1990, 100, 879-885.
M. Lazzaroni, et al.,Digestion37: 110-113 (1987).
E. Messori, et al.,Br. J. Pharmacol. 115, 677-683 (1995).
DR Nelson et al.Biochem. Pharmacol., 1989, 38(10), 1693-1695.
William D. Steers, et al.Drug Dev. Res. vol. 27, No. 4, 1992, pp. 361-375.
GJ Sanger and DR Nelson,Eur. J. Pharmacol., 1989, 159, 113-124.
M. Tonini, et al.Br. J. Pharmacol., 1994, 113, 1-2.
M. Turconi, et al.,Drugs of the Future, vol. 16, No. 11, 1991, pp. 1011-1026.
JW Upward et al.,Eur. J. Cancer, 1990, 26 (Suppl.), S12-S15.
S. Vaidyanathan,J. Urology, 1981, vol. 125 42-43.
H van den Brink et al,Eur. J. Pharmacol., 1990, 181(1-2), 119-125; (Chem Abs 1990, vol 113, p57, abstract 126402c).
Scand. J. Urology and Nephrology, 1979, 13, 79-82.
Sanger Gareth John
Wardle Kay Alison
Kinzig Charles M.
Kishore Gollumudi S.
McCarthy Mary E.
Oh Simon J.
Simon Soma G.
LandOfFree
Use of 5-HT4 modulators for the manufacture of a medicament... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 5-HT4 modulators for the manufacture of a medicament..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 5-HT4 modulators for the manufacture of a medicament... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3340861